SR One Capital Management Discloses 7.5% Stake in Avalyn Pharma Post-IPO

summarizeSummary

SR One Capital Management and its affiliates, including Simeon George, disclosed a 7.5% beneficial ownership stake in Avalyn Pharma Inc. following the company's initial public offering, acquired through preferred stock conversion and IPO participation.

check_boxKey Events

• Significant Institutional Ownership Disclosed

  SR One Capital Management and its affiliates, including Simeon George, reported a 7.5% beneficial ownership stake in Avalyn Pharma Inc.

• Post-IPO Stake Establishment

  The 3,308,649 shares were acquired through the conversion of preferred stock and participation in the recent IPO at $18.00 per share, formalizing a major investor's position after the company's public debut.

• Lock-up and Registration Rights

  The reporting persons are subject to a 180-day lock-up period post-IPO, preventing immediate sales, but also hold customary registration rights for future share dispositions.

auto_awesomeAnalysis

This Schedule 13D filing formalizes the significant ownership position of SR One Capital Management, a venture capital firm, and its managing member, Simeon George, in Avalyn Pharma Inc. post-IPO. The stake, totaling 3,308,649 shares, represents 7.5% of the company's common stock. The shares were acquired through a combination of preferred stock conversion and participation in the recent IPO at $18.00 per share. While the filing indicates the shares are held for investment purposes, it also highlights a 180-day lock-up agreement preventing immediate sales and outlines future registration rights, providing a pathway for potential liquidity. This disclosure confirms substantial institutional backing for Avalyn Pharma following its public debut.